This study found that next-day and 48-hour discharge following alternative access transcatheter aortic valve implantation were safe, with similar 30-day outcomes in terms of readmissions and mortality, supporting the expansion of these early discharge pathways for all TAVI patients.
This article highlights the need for increased awareness of sex-specific risks and biases in the management of acute coronary syndrome, with a focus on sex-specific bleeding mitigation strategies, appropriate antithrombotic management, and improving female representation in cardiovascular trials.
In this issue of EuroIntervention, there is an expert consensus from the EAPCI and the ESC Working Group on Thrombosis on antithrombotics and ACS in women. This issue also includes a debate on the current quantitative flow ratio guidelines. In original research, we look at short dual antiplatelet therapy in high bleeding risk patients with diabetes, pacemaker implantation in TAVI for aortic regurgitation, and chimney stenting in redo-TAVI. In a research correspondence, next-day discharge following TAVI via alternative vascular access is discussed. There is also a flashlight on transcaval transcatheter aortic valve implantation via left-sided venous access and a letter to the editor, news from EAPCI; and more...
We are pleased to share that EuroIntervention has achieved a new Impact Factor of 9.5, the highest in its 20-year history, confirming its place in the top quartile of cardiovascular publications with a ranking of 16 among 230 cardiology journals. This notable rise reflects the high standards of the Editorial Board and the ongoing contributions of our authors, reviewers, and readers.
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)